Route 92 Medical's HiPoint 88 Reperfusion System Achieves Record First Pass Effect in Stroke Thrombectomy Trial
• The SUMMIT MAX clinical trial demonstrated the HiPoint 88 Reperfusion System achieved an unprecedented 84% first pass effect in stroke thrombectomy procedures, significantly outperforming conventional catheters.
• Route 92 Medical has secured FDA 510(k) clearance for its HiPoint 88 Reperfusion System, becoming the first stroke treatment system with a super-bore direct aspiration label.
• The system's innovative design reduced the need for adjunctive devices by 49% compared to conventional catheters, potentially improving patient outcomes through faster blood flow restoration.
© Copyright 2025. All Rights Reserved by MedPath